Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/S2213-2600(21)00139-9 http://scihub22266oqcxt.onion/10.1016/S2213-2600(21)00139-9 33930329!8078877!33930329     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lancet+Respir+Med 2021 ; 9 (6): 655-664 Nephropedia Template TP {{tp|p=33930329|t=2021. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context |pdf=|usr=}}{{33930329}} gab.com Text Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context JO: Lancet Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=33930329 #FOAvip The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 signalling in patients with the disease. The efficacy and safety of tocilizumab and sarilumab, which block the binding of IL-6 to its receptor, have been tested in adults with COVID-19-related acute respiratory illness in randomised trials, with important differences in trial design, characteristics of included patients, use of co-interventions, and outcome measurement scales. In this Series paper, we review the clinical and methodological heterogeneity of studies of IL-6 receptor antagonists, and consider how this heterogeneity might have influenced reported treatment effects. Timing from clinical presentation to treatment, severity of illness, and concomitant use of corticosteroids are among the factors that might have contributed to apparently inconsistent results. With an understanding of the sources of variability in these trials, available evidence could be applied to guide clinical decision making and to inform the enrichment of future studies. Twit Text FOAVip Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context ????Lancet Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=33930329 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33930329 #FOAvip English Wikipedia <ref>{{Cite pmid|33930329}}</ref> Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context #MMPMID33930329 Angriman F; Ferreyro BL; Burry L; Fan E; Ferguson ND; Husain S; Keshavjee SH; Lupia E; Munshi L; Renzi S; Ubaldo OGV; Rochwerg B; Del Sorbo L Lancet Respir Med 2021[Jun]; 9 (6): 655-664 PMID33930329show ga The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 signalling in patients with the disease. The efficacy and safety of tocilizumab and sarilumab, which block the binding of IL-6 to its receptor, have been tested in adults with COVID-19-related acute respiratory illness in randomised trials, with important differences in trial design, characteristics of included patients, use of co-interventions, and outcome measurement scales. In this Series paper, we review the clinical and methodological heterogeneity of studies of IL-6 receptor antagonists, and consider how this heterogeneity might have influenced reported treatment effects. Timing from clinical presentation to treatment, severity of illness, and concomitant use of corticosteroids are among the factors that might have contributed to apparently inconsistent results. With an understanding of the sources of variability in these trials, available evidence could be applied to guide clinical decision making and to inform the enrichment of future studies. |*COVID-19/immunology/therapy[MESH] |*Clinical Trials as Topic/methods/statistics & numerical data[MESH] |Antibodies, Monoclonal, Humanized/immunology/*pharmacology[MESH] |Humans[MESH] |Patient Selection[MESH] |Receptors, Interleukin-6/*antagonists & inhibitors/immunology[MESH]Interleukin-6 receptor blockade in patients with COVID-19: placing cli(epmc).pdf DeepDyve Pubget Overpricing